Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic
- PMID: 34634250
- PMCID: PMC8500697
- DOI: 10.1016/S0140-6736(21)02143-7
Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic
Abstract
Background: Before 2020, mental disorders were leading causes of the global health-related burden, with depressive and anxiety disorders being leading contributors to this burden. The emergence of the COVID-19 pandemic has created an environment where many determinants of poor mental health are exacerbated. The need for up-to-date information on the mental health impacts of COVID-19 in a way that informs health system responses is imperative. In this study, we aimed to quantify the impact of the COVID-19 pandemic on the prevalence and burden of major depressive disorder and anxiety disorders globally in 2020.
Methods: We conducted a systematic review of data reporting the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic and published between Jan 1, 2020, and Jan 29, 2021. We searched PubMed, Google Scholar, preprint servers, grey literature sources, and consulted experts. Eligible studies reported prevalence of depressive or anxiety disorders that were representative of the general population during the COVID-19 pandemic and had a pre-pandemic baseline. We used the assembled data in a meta-regression to estimate change in the prevalence of major depressive disorder and anxiety disorders between pre-pandemic and mid-pandemic (using periods as defined by each study) via COVID-19 impact indicators (human mobility, daily SARS-CoV-2 infection rate, and daily excess mortality rate). We then used this model to estimate the change from pre-pandemic prevalence (estimated using Disease Modelling Meta-Regression version 2.1 [known as DisMod-MR 2.1]) by age, sex, and location. We used final prevalence estimates and disability weights to estimate years lived with disability and disability-adjusted life-years (DALYs) for major depressive disorder and anxiety disorders.
Findings: We identified 5683 unique data sources, of which 48 met inclusion criteria (46 studies met criteria for major depressive disorder and 27 for anxiety disorders). Two COVID-19 impact indicators, specifically daily SARS-CoV-2 infection rates and reductions in human mobility, were associated with increased prevalence of major depressive disorder (regression coefficient [B] 0·9 [95% uncertainty interval 0·1 to 1·8; p=0·029] for human mobility, 18·1 [7·9 to 28·3; p=0·0005] for daily SARS-CoV-2 infection) and anxiety disorders (0·9 [0·1 to 1·7; p=0·022] and 13·8 [10·7 to 17·0; p<0·0001]. Females were affected more by the pandemic than males (B 0·1 [0·1 to 0·2; p=0·0001] for major depressive disorder, 0·1 [0·1 to 0·2; p=0·0001] for anxiety disorders) and younger age groups were more affected than older age groups (-0·007 [-0·009 to -0·006; p=0·0001] for major depressive disorder, -0·003 [-0·005 to -0·002; p=0·0001] for anxiety disorders). We estimated that the locations hit hardest by the pandemic in 2020, as measured with decreased human mobility and daily SARS-CoV-2 infection rate, had the greatest increases in prevalence of major depressive disorder and anxiety disorders. We estimated an additional 53·2 million (44·8 to 62·9) cases of major depressive disorder globally (an increase of 27·6% [25·1 to 30·3]) due to the COVID-19 pandemic, such that the total prevalence was 3152·9 cases (2722·5 to 3654·5) per 100 000 population. We also estimated an additional 76·2 million (64·3 to 90·6) cases of anxiety disorders globally (an increase of 25·6% [23·2 to 28·0]), such that the total prevalence was 4802·4 cases (4108·2 to 5588·6) per 100 000 population. Altogether, major depressive disorder caused 49·4 million (33·6 to 68·7) DALYs and anxiety disorders caused 44·5 million (30·2 to 62·5) DALYs globally in 2020.
Interpretation: This pandemic has created an increased urgency to strengthen mental health systems in most countries. Mitigation strategies could incorporate ways to promote mental wellbeing and target determinants of poor mental health and interventions to treat those with a mental disorder. Taking no action to address the burden of major depressive disorder and anxiety disorders should not be an option.
Funding: Queensland Health, National Health and Medical Research Council, and the Bill and Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests C Adolph reports support from the Benifcus Foundation. A Flaxman holds stock in Agathos, and consults and advises Janssen, SwissRe, Sanofi, and Merck for Mothers on simulation modeling, outside of the submitted work. S Nomura reports support from the Ministry of Education, Culture, Sports, Science and Technology of Japan. All other authors declare no competing interests.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8586734/bin/gr1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8586734/bin/gr2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8586734/bin/gr3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8586734/bin/gr4.gif)
Comment in
-
Depression and anxiety disorders during the COVID-19 pandemic: knowns and unknowns.Lancet. 2021 Nov 6;398(10312):1665-1666. doi: 10.1016/S0140-6736(21)02221-2. Epub 2021 Oct 8. Lancet. 2021. PMID: 34634251 Free PMC article. No abstract available.
-
Depression and anxiety during COVID-19 - Authors' reply.Lancet. 2022 Feb 5;399(10324):518-519. doi: 10.1016/S0140-6736(21)02800-2. Lancet. 2022. PMID: 35123688 Free PMC article. No abstract available.
-
Depression and anxiety during COVID-19.Lancet. 2022 Feb 5;399(10324):518. doi: 10.1016/S0140-6736(22)00187-8. Lancet. 2022. PMID: 35123689 Free PMC article. No abstract available.
Similar articles
-
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.Lancet. 2024 May 18;403(10440):1989-2056. doi: 10.1016/S0140-6736(24)00476-8. Epub 2024 Mar 11. Lancet. 2024. PMID: 38484753 Free PMC article.
-
Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet Psychiatry. 2022 Feb;9(2):137-150. doi: 10.1016/S2215-0366(21)00395-3. Epub 2022 Jan 10. Lancet Psychiatry. 2022. PMID: 35026139 Free PMC article.
-
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet. 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. Lancet. 2017. PMID: 28919117 Free PMC article.
-
Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010.Lancet. 2013 Nov 9;382(9904):1564-74. doi: 10.1016/S0140-6736(13)61530-5. Epub 2013 Aug 29. Lancet. 2013. PMID: 23993281 Review.
-
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.Lancet. 2013 Nov 9;382(9904):1575-86. doi: 10.1016/S0140-6736(13)61611-6. Epub 2013 Aug 29. Lancet. 2013. PMID: 23993280 Review.
Cited by
-
Optimising the use of electronic medical records for large scale research in psychiatry.Transl Psychiatry. 2024 Jun 1;14(1):232. doi: 10.1038/s41398-024-02911-1. Transl Psychiatry. 2024. PMID: 38824136 Free PMC article. Review.
-
Factor structure and measurement invariance of the Patient Health Questionnaire-4 among the Chilean population.PLoS One. 2024 May 31;19(5):e0304623. doi: 10.1371/journal.pone.0304623. eCollection 2024. PLoS One. 2024. PMID: 38820399 Free PMC article.
-
Walk-in mental health: Bridging barriers in a pandemic.PLoS One. 2024 May 31;19(5):e0302543. doi: 10.1371/journal.pone.0302543. eCollection 2024. PLoS One. 2024. PMID: 38820293 Free PMC article.
-
Psychogenic Aging: A Novel Prospect to Integrate Psychobiological Hallmarks of Aging.Transl Psychiatry. 2024 May 30;14(1):226. doi: 10.1038/s41398-024-02919-7. Transl Psychiatry. 2024. PMID: 38816369 Free PMC article. Review.
-
Digital mental health and peer support: Building a Theory of Change informed by stakeholders' perspectives.PLOS Digit Health. 2024 May 30;3(5):e0000522. doi: 10.1371/journal.pdig.0000522. eCollection 2024 May. PLOS Digit Health. 2024. PMID: 38814923 Free PMC article.
References
-
- Patel V, Chisholm D, Parikh R, et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. Lancet. 2016;387:1672–1685. - PubMed
-
- Institute for Health Metrics and Evaluation . Institute for Health Metrics and Evaluation, University of Washington; Seattle, WA: 2020. COVID-19 projections.https://covid19.healthdata.org/
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous